For patients with secondary HPT on dialysis,
How do you know if your PTH, calcium, and phosphorus are too high or too low?
- Your dialysis care team will decide your goal ranges for PTH, calcium, and phosphorus.1
Ask your dialysis care team what your goal ranges are.
It is important to keep your PTH, calcium, and phosphorus in their goal range at the same time.
- It can be harmful to your health if one level is too high or too low, even if the other two are in their goal range.2
Are your PTH, calcium, and phosphorus in their goal range at the same time?
Next Section
Sensipar® is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.
Important Safety Information
- Sensipar® treatment should not be started if you have low calcium levels.
Ask your doctor about the normal ranges.
- Before starting Sensipar®, tell your doctor if you are taking medication to
prevent seizures or have had seizures in the past. Report any seizure episodes while on
Sensipar® therapy.
- Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart
rhythm (arrhythmia) have been reported in patients with impaired heart function taking
Sensipar®.
- While on Sensipar®, your doctor should perform repeated blood tests to monitor
calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels
of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH
may cause a condition your doctor may refer to as adynamic bone disease.
- Patients with moderate to severe liver impairment should be monitored throughout treatment
with Sensipar®.
- Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs,
or seizures.
- In clinical trials, the most common side effects reported in patients were nausea, vomiting,
and diarrhea.
If you have any questions about this information, be sure to discuss them with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (332-1088).
References:
1. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD–mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2010;55:773-799.
2. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1423-1429.
